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OBJECTIVES: Chronic Myeloid Leukemia (CML) is a myeloproliferative disease as-
sociated with a chromosomal translocation (Philadelphia chromosome). Since
2003 life-long treatment by Tyrosine Kinase Inhibitors (TKIs) have dramatically
improved survival. The objective of this study was to predict the characteristics of
the population under TKI treatment at the horizon 2015. METHODS: An epidemi-
ological model was developed over the period 2003-2015 on first and following line
therapies, combining demographic, incidence, prevalence, survival data and prob-
ability of resistance or intolerance in each line. Data were derived from published
randomized clinical studies. The model was tested over the period 2003-2009 by
comparison with retrospective market data and then extrapolated to the period
2010-2015. RESULTS: At the time of the first TKI launch (imatinib) in 2003, a prev-
alent group of 1,878 patients started treatment. Second-generation TKIs dasatinib
and nilotinib were then made available in France between November 2007 and May
2008 as second line therapy, and potentially in mid-2011 as first line. Despite a
stable annual number of 600 incident cases (1.25 x10-5) of CML eligible for a TKI first
line treatment, the total number of patients under treatment increased to 7260 in
2010 (a 3.9-fold increase since 2003) of which 1083 were in second line (15%). The
extrapolation model predicted a total of 10,069 treated patients in 2015 of which
1,618 in second line (16%) representing a 39% 5-year increase. CONCLUSIONS: The
dramatic overall survival benefit associated with TKIs was a key factor for explain-
ing the growth of the CML treated population aside from the emergence of second
line therapies.
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OBJECTIVES: With 75,880 patients under medical supervision in 2007, prostate
cancer is the fourth most frequent cancer in Russia and the first in terms of in-
crease of mortality (21,6%) with ,8909 deaths/year. Moreover metastatic prostate
cancer (MPCa) holds more than 60% of these patients at the same time being the
leading expenditure driver. The purpose of this study was to evaluate the burden of
illness and total per patient costs, associated with managing patients with (MPCa)
in the 12 months following diagnosis in Russia from perspective of public health-
care system. METHODS: A costing model combined the data of official algorithms
(standard of treatment approved by Ministry of Health) and guidelines of MPCa
management, as well as local experts opinion and published data on resource use
and unit costs from published sources to calculate total per patient direct costs of
MPCa treatment. Direct costs of MPCa include expenses on medical services and
pharmacotherapy (cytostatics, hormones and antihormones, accompanying and
other drugs). As initial treatment following diagnosis radiotherapy was used most
frequently. Use of chemotherapy was low. Relapse and mortality were not factored
into the model. Total direct medical costs of initial treatments following diagnosis
per patient were calculated for MPCa in 12 months timeframe. RESULTS: Total per
patient direct costs following diagnosis was 810,529 roubles. Analysis of the costs
structure showed that hormone therapy represents a significant higher cost to
surgery, while radiotherapy had the highest cost proportion. Pharmacotherapy
was the major driver of MPCa treatment cost (more than 50% share from all
expenditures). CONCLUSIONS: In this study quantifying the cost of MPCa treat-
ment in Russia was found a significant resource utilization and healthcare costs,
along with the major cost drivers. Given the number of new cases diagnosed in
Russian Federation, these estimates suggest a large total spending on the disease.
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OBJECTIVES: In 2008, the annual medical expenditure on cancer treatment in Japan
was approximately 16 trillion yen. In the past decade, a few molecular-targeted
drugs (MTDs) were developed for the treatment of HER2metastatic breast cancer
(HER2-MBC). The number of MTD-treated patients increases every year, which is a
concern with regard to the economic impact of cancer therapy. Trastuzumab is the
most popular alternative to HER2-MBC therapy in Japan, but it has a high national
health insurance price of approximately 220,000 yen per month for women weigh-
ing 50 kg. To estimate the clinical and economic burden of breast cancer (BC) and
HER2-MBC therapies, we commenced a large clinical database survey, by examin-
ing the diagnosis procedure combination (DPC)–based claims, which included flat
payment schemes. METHODS: The database, which consists of 15 DPC-targeted
institutions that had contracted with Medical Data Vision Ltd., includes approxi-
mately 400,000 patients. To extract the pertinent population and estimate the clin-
ical and economic burden of MTDs, a target population consisting of individuals
diagnosed with BC on or before March 31, 2010, aged more than 20 years, and
treated with MTDs for HER2-MBC was chosen. The observation period was April 1,
2008 to March 31, 2010. RESULTS: During the observation period, 2,419 individuals
were diagnosed with BC. Of these, 98 were receiving or had received MTDs. The
observed estimated economic cost of BC treatment was 994,000 yen, with an ob-
servation duration of approximately 14.0 person-months. The cost of HER2-MBC
treatment with MTDs was estimated at 4,455,000 yen with a duration of 17.4 per-
son-months. CONCLUSION: HER2-MBC therapy seriously impacted the annual
medical expenditure in Japan and had a rare survival duration. The database was
useful for conducting an economic analysis of cancer treatment in Japan.
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OBJECTIVES: To estimate direct medical costs of Tuberous Sclerosis Complex with
neurological and developmental manifestations under the Brazilian public health
care system perspective (SUS). METHODS: A retrospective database analysis was
developed from ICD-10 search from January/2008 (revision of table of procedures by
SUS Information Technology Department/DATASUS) to February/2011. Neurolog-
ical and developmental manifestations of TSC included in the study were sub-
ependymal giant cell astrocytoma (SEGA), epilepsy, epileptic syndromes/infantile
spasm, mental disability and autism, based on prevalences and expected costs to
SUS. Direct medical costs per patient per year for each manifestation were esti-
mated based on DATASUS ambulatory (high complexity) and hospital settings,
whose databases included 2,016,188 and 9,236,360 persons, respectively. Epidemi-
ologic literature was applied to correct misreported data and estimate average cost
per patient per year for all manifestations. Sensitivity analysis was performed for
the prevalence of manifestations. Costs were reported in 2010 Reals. RESULTS: The
most prevalent procedure (and respective unit cost) for SEGA, epilepsy/epileptic
syndromes/infantile spasm, and mental disability/autism were surgery (R$6302),
hospitalization for uncontrolled seizure (R$585) and anti-epileptic drugs (R$1887),
and psychiatric ambulatory treatment (R$275/R$892), respectively. The average
direct medical costs per patient per year at SUS were R$7672 for SEGA, R$2,570 for
epilepsy, R$1,349 for epileptic syndromes/infantile spasm, R$4668 for mental dis-
ability and R$2,276 for autism. Average cost per patient per year for all manifesta-
tions was R$19,180. This cost varied from R$13,580 to R$22,556 in sensitivity anal-
ysis. TSC neurological and developmental manifestation costs are expected to be
underestimated due to lack of access and provision of health services, mainly in
long-term disorders. CONCLUSIONS: TSC neurological and developmental mani-
festations impose significant economic burden to the Brazilian public health care
system. However, the real economic burden is potentially higher as the diagnosis
and treatment of the disease and its manifestations are underestimated consider-
ing restrictions of access and health service provision.
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OBJECTIVES: To review incidence rate and burden of illness associated with Hu-
man Papillomavirus (HPV) related female genital (cervical, vulvar and vaginal) can-
cers in Spain. METHODS: Databases and registries searched for data retrieval in-
cluded EMBASE, PUBMED, Cochrane, Globocan, WHO, SEER and relevant grey
literature. Studies reporting epidemiology and costs associated with HPV-related
genital cancers in females were of interest. RESULTS: In 2008, age standardized
incidence rate of cervical cancer per 100,000 females was 6.3 in Spain compared to
5.7, 7.2, 10.6 and 15.3 in US, UK, Europe and worldwide, respectively (Globocan
2008). The incidence of cervical cancer was highest among Spanish women aged
45-54 years. Incidence rate of vulvar and vaginal cancers ranged from 1.6-4.0 and
0.3-0.7 per 100,000 females, respectively. Additionally, vulvar and vaginal cancers
were most common among older women (70 and 65 years, respectively). In the
same year (2008), mortality rate due to cervical cancer was 1.9 per 100,000 females
(WHO 2010). Mortality rate for vulvar-vaginal cancer was 9.34% from 1997-2008
(Gil-prieto 2011). Annually, 7.6 million pap smear tests were performed in Spain at
the cost of €622 million (Castellsague 2009). Average number of hospitalizations per
year was 4151 due to cervical cancer and 17,883 due to vulvar-vaginal cancers.
Mean (SD) length of hospital stay due to cervical cancer was 8.7 (15.2) days and 8 (10)
days due to vulvar-vaginal cancer (Gil 2007, Gil-prieto 2011). Estimated annual cost
of hospitalization due to cervical cancer and carcinoma in situ was €19 million (Gil
2007). Indirect costs (productivity loss) associated with mortality related to cervical
cancer were €1.1 million (Oliva 2006). CONCLUSIONS: HPV-related genital cancers
have significant incidence and mortality rate in Spanish women with higher risk in
elderly female population. The direct and indirect costs incurred due to genital
cancers are substantial and reflect considerable economic burden.
PCN50
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OBJECTIVES: Because treatment options for lung cancer are changing rapidly, it is
important to understand current treatment patterns and cost implications. We
conducted a retrospective claims analysis to identify common lung cancer regi-
mens and direct medical costs in a large US commercial health insurance and
Medicare Advantage database. METHODS: We identified patients with lung cancer
receiving 1st or 2nd line chemotherapy between January 2006 to December 2010
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